The increasing cases of diabetes across the globe is projected to propel the global diabetic neuropathy market during 2019-2026. Fortune Business Insights, in a report, titled “Diabetic Neuropathy Market Size, Share and Global Trend By Type (Peripheral, Proximal, Autonomic, Focal), By Drug Class (Non-steroidal Anti-inflammatory Drugs, Antisiezure Drugs, Opioid Drugs, Anti-depressants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026,” states that various factors such as urbanization, change in the genetic compositions, and increasing sedentary lifestyle have increased the incidence of cardiovascular diseases and cases of obesity. These factors are likely to boost the global diabetic neuropathy market during the forecast period.
The National Institute of Neurological Disorders and Stroke recently supplied funds for research and development activities on neuropathy. Similarly, numerous non-profit organizations are taking initiatives to control diabetes in developing countries. Fortune Business Insights predicts that this factor is likely to boost the global diabetic neuropathy market by the end of 2026. But, diabetic neuropathy drugs are costly and this is one of the major factors that is anticipated to hamper the growth of global diabetic neuropathy market. Also, the lack of complete treatment of neuropathy and side effects of the drugs are likely to pose as obstacles for the growth of the global diabetic neuropathy market.
Top Key Players Covered:
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Lupin Pharmaceuticals
- Lupin Global
- Akorn, Inc
- Eli Lilly and Company
- GlaxoSmithKline Pharma GmbH
- Glenmark Pharmaceuticals
- Assertio Therapeutics, Inc.
- Astellas Pharma US
The report classifies the global diabetic neuropathy market on various bases, namely by drug class, by type, by geography, and by distribution channel. In terms of drug class, the market is further segmented into non-steroidal anti-inflammatory drugs, opioid drugs, anti-depressants, antisiezure drugs, and others. The non-steroidal anti-inflammatory drugs was leading the global diabetic neuropathy market back in 2018. However, due to new administration techniques and a rise in the number of approvals for opioid medicines, the opioid drug segment is projected to gain higher CAGR during the forecast period.
By Drug Class
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Antisiezure Drugs
- Opioid Drugs
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
More Trending Topics From Fortune Business [email protected]